Discussing the approval of Enhertu as the first HER2-directed therapy in patients with HER2-low metastatic breast cancer

Executed on:Aug 12, 2022 4:00 PM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

Institution: UC San Diego Health

Associate professor of Clinical Medicine and Scientific Director of Inflammatory and Triple Negative Breast Cancer Program at UC San Diego Health.
Principal investigator of many clinical trials and is part of the national clinical operations leadership for the I-SPY-2 trial focusing on the treatment of triple negative breast cancer.
Has published numerous papers on the topic of metastatic breast cancer in in JAMA Oncology, Cancer Cell and Molecular Cancer Therapeutics, among others.
Manages over 300 patients with HER2 low breast cancer and currently prescribes Enhertu

Interview Goal

This conversation will focus on discussing the recent FDA approval of Enhertu as the first HER2- directed therapy in patients with HER2- low metastatic breast cancer

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.